Methods of treating cognitive impairment

Patent metadata

Field	Value
Publication number	US-2021106654-A1
Application number	US-202016938736-A
Country	US
Kind code	A1
Filing date	Jul 24, 2020
Priority date	Aug 5, 2008
Publication date	Apr 15, 2021
Grant date	—

Abstract

Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

First claim

We claim:

1 . A method for treating cognitive impairment in a person or animal or for improving congintion in a person or animal comprising administering to the person or animal an effective amount of one or more inflammatory mediator(s), or a composition comprising said one or more inflammatory mediator(s), wherein said inflammatory mediator comprises one or more of granulocyte colony-stimulating factor (G-CSF), filgrastin, pegfilgrastin, granulocyte/macrophage colony-stimulating factor (GM-CSF), or sargramostim, wherein said inflammatory mediator is able to cross the blood brain barrier and treats cognitive impairment or improves cognition in the person or animal.

2 . (canceled)

3 . The method of claim 1 , wherein said inflammatory mediator comprises GM-CSF.

4 . The method of claim 1 , wherein said inflammatory mediator comprises a biological equivalent of GM-CSF.

5 . The method of claim 1 , wherein said inflammatory mediator is capable of reducing amyloid beta levels in the plasma or brain of the treated person or animal.

6 . The method of claim 3 , wherein said GM-CSF is capable of reducing neural tangles in the plasma or brain of the treated person or animal.

7 . The method of claim 1 , wherein the cognitive impairment is caused by or results from Alzheimer's disease.

8 . The method of claim 1 , wherein the inflammatory mediator is administered intracranially.

9 . The method of claim 1 , wherein the inflammatory mediator is administered by intracranial infusion.

10 . The method of claim 1 , wherein the inflammatory mediator is administered to a non-neural cell or tissue.

11 . The method of claim 1 , wherein said method further comprises evaluating the person or animal for cognitive impairment prior to treatment.

12 . The method of claim 1 , wherein said composition comprises a pharmaceutically acceptable carrier, diluent, or solute.

13 - 16 . (canceled)

17 . The method of claim 1 , wherein said cognitive impairment is caused by or results from stroke, Down's syndrome, dementia pugilistica, traumatic brain injury, AIDS-associated associated dementia, Lewy body disease, or Pick's disease.

18 . The method of claim 1 , wherein i) G-CSF and/or GM-CSF and ii) Darbepoetin and/or EPO are administered to the person or animal.

19 . A method for reducing the level of an amyloid beta (A13) peptide in the brain of a person or animal, comprising administering to the person or animal an effective amount of a granulocyte/macrophage colony-stimulating factor (GM-CSF) or sargramostim, or a composition comprising GM-CSF or sargramostim, wherein the level of an Aβ peptide is reduced in the person or animal relative to the level of Aβ peptide in the brain of the person or animal prior to administration of the GM-CSF.

20 . A method for increasing the synaptic density in the brain of a person or animal, comprising administering to the person or animal an effective amount of a granulocyte/macrophage colony-stimulating factor (GM-CSF) or sargramostim, or a composition comprising GM-CSF or sargramostim, whereby the person or animal exhibits increased synaptic density relative to the level of synaptic density in the brain of the person or animal prior to administration of GM-CSF.

21 . The method according to claim 5 , wherein said amyloid beta is an amyloid beta (Aβ) peptide designated as Aβ peptide 1-37, Aβ peptide 1-38, Aβ peptide 1-39, Aβ peptide 1-40, Aβ peptide 1-42, Aβ peptide I 1-40, or Aβ peptide 11-42.

22 . The method according to claim 21 , wherein said Aβ peptide is present in said person or animal as an extracellular amyloid plaque.

23 . The method according to claim 3 , wherein said GM-CSF is human GM-CSF.

24 . The method according to claim 3 , wherein said GM-CSF comprises the amino acid sequence of SEQ ID NO: 1, or said GM-CSF has greater than 90% sequence identity with the amino acid sequence of SEQ ID NO: 1.

25 . The method according to claim 19 , wherein said GM-CSF is human GM-CSF.

26 . The method according to claim 19 , wherein said GM-CSF comprises the amino acid sequence of SEQ ID NO: 1, or said GM-CSF has greater than 90% sequence identity with the amino acid sequence of SEQ ID NO: 1.

Assignees

• Univ South Florida

Inventors

• Potter Huntington
• Arendash Gary W
• Bennett Steven
• Boyd Timothy

Classifications

• A61K38/19 Primary

  Cytokines; Lymphokines; Interferons · CPC title

• A61K38/18

  Growth factors; Growth regulators · CPC title

• A61K38/20

  Interleukins [IL] · CPC title

• A61K38/193 Primary

  Colony stimulating factors [CSF] · CPC title

• A61K38/1816

  Erythropoietin [EPO] · CPC title